Abstract: The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result.

Abstract: A reaction container in which to mix a first chemical compound with a second chemical compound has a main body and a lid member formed oppositely on a top face side of the main body; a flow channel on the top face of the main body; and a labeling agent solidification section at an intermediate section of the flow channel to remove a solvent in a solution of the second chemical compound and solidify the second chemical compound. First and second chemical compound supply sections and a mixture discharge section are formed on the upstream and downstream sides of the labeling agent solidification section, respectively. The reactor is provided with a liquid sending unit to supply the first and second chemical compounds and reciprocally send a solution of the first chemical compound to an upper part of the second chemical compound solidified at the solidification section.

Abstract: In a reaction between a biomolecule and a radioactive agent precursor, the amount of a component of a radioactive agent precursor before the reaction and the amount of a component contained in a reaction mixture in a reaction process in which the reaction is performed at a predetermined biomolecule concentration are measured, a reaction rate constant is calculated from the information of the obtained amounts of the components, a reaction rate constant when the biomolecule concentration is changed is calculated, a reaction time, a specific radioactivity, and a radioactivity level of an objective substance at each biomolecule concentration are predicted, and synthesis is performed under a reaction condition under which the highest specific radioactivity is obtained among the reaction conditions satisfying the synthesis requirements.

Abstract: The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result.

Abstract: A reaction container in which to mix a first chemical compound with a second chemical compound has a main body and a lid member formed oppositely on a top face side of the main body; a flow channel on the top face of the main body; and a labeling agent solidification section at an intermediate section of the flow channel to remove a solvent in a solution of the second chemical compound and solidify the second chemical compound. First and second chemical compound supply sections and a mixture discharge section are formed on the upstream and downstream sides of the labeling agent solidification section, respectively. The reactor is provided with a liquid sending unit to supply the first and second chemical compounds and reciprocally send a solution of the first chemical compound to an upper part of the second chemical compound solidified at the solidification section.

Abstract: Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

Abstract: A method is provided for diagnosing or predicting atherosclerosis with the use of, as indicators, markers (factors) that allow early detection and progression prediction of the disease and a method for evaluating preventive or therapeutic effects. In one form, the present method includes detecting CD166 (ALCAM) level in a sample of a subject such as human. Another aspect of the present method includes evaluating preventive or therapeutic effects of a compound on atherosclerosis. A kit and an apparatus for carrying out such methods is also provided.

Abstract: The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result.

Abstract: Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

Abstract: In quantitation without using the isotope labeling technique, there is no means to detect the presence/absence and the time region of the occurrence of quantitative analysis-inhibitory factors in data for the analysis, and the reliability of the data for the analysis cannot be evaluated. Also, the error of the data due to the occurrence of the quantitative analysis-inhibitory factors cannot be evaluated. In order to solve the problems, first, an internal standard to be detected simultaneously with a component for the analysis is mixed in a mobile phase or an eluate of a liquid chromatograph; under the condition where no quantitative analysis-inhibitory factors occur, a blank sample is analyzed to acquire a mass chromatogram of ions originated from the internal standard; and the result is stored in a data storage unit.

Abstract: Since atherosclerosis induces cerebral infarction and myocardial infarction, a method for diagnosing or predicting atherosclerosis with the use of, as indicators, markers (factors) that allow early detection and progression prediction of the disease and a method for evaluating preventive or therapeutic effects have been awaited. This invention provides a method for diagnosing or predicting atherosclerosis which comprises detecting CD166 (ALCAM) level in a sample of a subject such as human, a method for evaluating preventive or therapeutic effects of a compound on atherosclerosis, and a kit and an apparatus for carrying out such methods.

Abstract: An inexpensive mass spectrometer system is provided. This mass spectrometer is capable obtaining structural information of a substance at an improved efficiency, and the time required for the analysis and identification of the substance has been reduced. Identification precision has also been improved. More specifically, this invention provides a tandem mass spectrometer system in which the sample is ionized at the desired polarity, fragment ions obtained by dissociating the ion is analyzed in first or second mass spectrometer section, polarity of the second mass spectrometer is determined based on the result of the analysis, and the mass spectroscopy is carried out. A method for the mass spectroscopy is also provided.

Abstract: An inexpensive mass spectrometer system is provided. This mass spectrometer is capable obtaining structural information of a substance at an improved efficiency, and the time required for the analysis and identification of the substance has been reduced. Identification precision has also been improved. More specifically, this invention provides a tandem mass spectrometer system in which the sample is ionized at the desired polarity, fragment ions obtained by dissociating the ion is analyzed in first or second mass spectrometer section, polarity of the second mass spectrometer is determined based on the result of the analysis, and the mass spectroscopy is carried out. A method for the mass spectroscopy is also provided.